Standout Papers

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors 2024 202653
  1. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors (2024)
    Sarah Cook, Daniel E. Meyers et al. JAMA Network Open

Immediate Impact

1 by Nobel laureates 60 standout
Sub-graph 1 of 24

Citing Papers

Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
2025 Standout
The B7:CD28 family and friends: Unraveling coinhibitory interactions
2024 Standout
3 intermediate papers

Works of Daniel E. Meyers being referenced

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database
2021
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Daniel E. Meyers 386 168 58 102 41 577
Navdeep Pal 182 120 59 88 26 634
Todd C. Knepper 292 115 43 113 38 589
Eucario León-Rodrı́guez 267 105 30 131 46 612
Yining Ye 230 127 40 148 28 654
Yunan Han 313 204 29 148 39 660
N. Iscoe 353 167 37 131 25 579
Samuel M. Rubinstein 277 87 27 132 42 597
Pauline de Graeff 255 126 41 252 34 732
Kelsey L. Corrigan 282 95 49 93 52 551
Gustavo dos Santos Fernandes 172 87 21 148 51 605

All Works

Loading papers...

Rankless by CCL
2026